0001567619-21-001669.txt : 20210128 0001567619-21-001669.hdr.sgml : 20210128 20210128165926 ACCESSION NUMBER: 0001567619-21-001669 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210126 FILED AS OF DATE: 20210128 DATE AS OF CHANGE: 20210128 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lackner Mark CENTRAL INDEX KEY: 0001777413 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38915 FILM NUMBER: 21566054 MAIL ADDRESS: STREET 1: C/O IDEAYA BIOSCIENCES, INC. STREET 2: 7000 SHORELINE COURT, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IDEAYA Biosciences, Inc. CENTRAL INDEX KEY: 0001676725 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474268251 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7000 SHORELINE COURT, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-443-6209 MAIL ADDRESS: STREET 1: 7000 SHORELINE COURT, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Ideaya Biosciences, Inc. DATE OF NAME CHANGE: 20160609 4 1 doc1.xml FORM 4 X0306 4 2021-01-26 0 0001676725 IDEAYA Biosciences, Inc. IDYA 0001777413 Lackner Mark C/O IDEAYA BIOSCIENCES, INC. 7000 SHORELINE COURT, SUITE 350 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 SVP, Head of Biology Common Stock 2021-01-26 4 M 0 377 4.62 A 1378 D Common Stock 2021-01-26 4 M 0 1123 6.98 A 2501 D Common Stock 2021-01-26 4 S 0 1701 18.2977 D 800 D Common Stock 2021-01-26 4 S 0 800 18.7919 D 0 D Stock Option (right to buy) 4.62 2021-01-26 4 M 0 377 0.00 D 2028-06-20 Common Stock 377 61760 D Stock Option (right to buy) 6.98 2021-01-26 4 M 0 1123 0.00 D 2028-12-11 Common Stock 1123 35014 D Includes 1,001 shares acquired pursuant to Issuer's Employee Stock Purchase Plan on November 30, 2020. The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. This transaction was executed in multiple trades in prices ranging from $17.68 to $18.62, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $18.68 to $18.895, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. 25% of the shares subject to the option vest on the first anniversary measured from May 31, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. 25% of the shares subject to the option vest on the first anniversary measured from December 11, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. /s/ Jason Throne, as Attorney-in-Fact for Mark Lackner 2021-01-28